Tuis0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Vorige sluiting
$0,41
Dagwisseling
$0,41 - $0,42
Jaarwisseling
$0,30 - $0,62
Markkapitalisasie
3,94 mjd HKD
Gemiddelde volume
887,22 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
HKG
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (HKD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,32 mjd | 2,20% |
Bedryfskoste | 323,51 m | -4,23% |
Netto inkomste | 500,50 k | -97,29% |
Netto winsgrens | 0,04 | -97,20% |
Wins per aandeel | — | — |
EBITDA | 117,12 m | 36,03% |
Effektiewe belastingkoers | 79,96% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (HKD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 562,09 m | 11,10% |
Totale bates | 10,89 mjd | -1,45% |
Totale aanspreeklikheid | 6,87 mjd | -0,11% |
Totale ekwiteit | 4,01 mjd | — |
Uitstaande aandele | 9,61 mjd | — |
Prys om te bespreek | 0,98 | — |
Opbrengs op bates | 1,75% | — |
Opbrengs op kapitaal | 1,91% | — |
Kontantvloei
Netto kontantverandering
| (HKD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 500,50 k | -97,29% |
Kontant van bedrywe | 72,70 m | 80,63% |
Kontant van beleggings | -47,88 m | -484,81% |
Kontant van finansiering | -77,72 m | 41,39% |
Netto kontantverandering | -57,56 m | 42,02% |
Beskikbare kontantvloei | 35,56 m | 91,21% |
Meer oor
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
HUB
Gestig
2000
Webwerf
Werknemers
1 968
